CoChat

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs

Open access
Virani, Salim S., Akeroyd, Julia M., Nambi, Vijay, Heidenreich, Paul A., Morris, Pamela B., Nasir, Khurram, Michos, Erin D., Bittner, Vera A., Petersen, Laura A., Ballantyne, Christie M. · 2017 · Circulation
Cited by 60

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

I n the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), 1 treatment with evolocumab resulted in a 15% relative (1.5% absolute) risk reduction of major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) at a median follow-up of 2.2 years.This trial included patients with low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL or non-high-density lipoprotein cholesterol ≥100 mg/dL on at least moderate-intensity statins.It is not known what proportion of patients with ASCVD would qualify for evolocumab on the basis of FOURIER entry criteria and how eligibility would change if maximal doses of evidence-based lipid-lowering therapies were required.We assessed the number and proportion of US veterans with ASCVD who would qualify for evolocumab on the basis of FOURIER trial entry criteria and how these figures would change if high-intensity statins, ezetimibe, or the combination of both agents were used.Using a cohort of veterans with ASCVD (myocardial infarction, ischemic stroke, or peripheral arterial disease) receiving care in the Veterans Affairs (VA) system between October 2013 and September 2014, we identified all patients with ASCVD 40 to 85 years of age (n=631 855) using previously described algorithms with a positive predictive value of 88% in correctly identifying patients with ASCVD. 2 We identified patients meeting 1 major or 2 minor FOURIER protocol criteria and excluded patients with LDL-C <70 mg/dL or non-high-density lipoprotein cholesterol <100 mg/dL, those not receiving at least moderate-intensity statins, those with triglycerides >400 mg/dL, and those meeting other FOURIER exclusions. 1 Among patients meeting FOURIER inclusion and exclusion criteria, we determined proportions receiving moderate-intensity statins (30%-<50% LDL-C reduction), high-intensity statins (≥50% LDL-C reduction), 3 or a combination of moderate-or high-intensity statin and ezetimibe using VA pharmacy records.We then used 3 clinical scenarios to model how eligibility for evolocumab would change (on the basis of an LDL-C reduction to <70 mg/dL) if all patients were titrated to a high-intensity statin (assuming 6% LDL-C reduction with each statin dose doubling), ezetimibe use (assuming a 20% LDL-C reduction), 4 or a combination of high-intensity statin plus ezetimibe.Associated costs were estimated assuming a $0.07/d increment for titration to high-intensity statin, $2/d for the addition of generic ezetimibe, and $13 462.28/y for evolocumab.5 The protocol was approved by the Institutional Review boards at Baylor College of Medicine and the Michael E. DeBakey VA Medical Center.Among 631 855 patients with ASCVD who were 40 to 85 years of age, 154 823 (24.5%) would be evolocumab eligible with the use of FOURIER inclusion/exclusion criteria.The largest proportion were excluded because of LDL-C <70 or non-highdensity lipoprotein cholesterol <100 mg/dL (38.2%).However, only half (49.9%) of those who qualified were on high-intensity statins, whereas 47.5% were on moderate-intensity statins, and 2.6% were on a statin/ezetimibe combination.Mean

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.028503

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 60

Metadata

Authors
Virani, S. S., Akeroyd, J. M., Nambi, V., Heidenreich, P. A., Morris, P. B., Nasir, K., Michos, E. D., Bittner, V. A., Petersen, L. A., & Ballantyne, C. M.
Venue
Circulation
Published
2017-06-20
Volume
135
Issue
25
Pages
2572-2574
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2656846000
Cited by
60
References
2
FWCI
9.60
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. https://app.cochat.ai/papers/10.1161/circulationaha.117.028503
The paper
Virani, S. S., Akeroyd, J. M., Nambi, V., Heidenreich, P. A., Morris, P. B., Nasir, K., Michos, E. D., Bittner, V. A., Petersen, L. A., & Ballantyne, C. M. (2017). Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. https://doi.org/10.1161/circulationaha.117.028503

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.